Faster global financial news!
Pfizer
-
Alnylam Pharmaceuticals' stock price has fallen by approximately 40% this year, but Wall Street analysts generally remain optimistic, with an average target price indicating about 50% upside potential.
Shares of biotechnology company Alnylam Pharmaceuticals (Nasdaq: ALNY) have fallen by approximately 40% year-to-date, but Wall Street analysts remain largely optimistic about its prospects. According
-
Yahoo Finance Analysis: Four High-Yield Dividend US Stocks Recommended, Including Pfizer and Altria
Yahoo Finance analysts recommend four high-yield dividend stocks suitable for a Roth IRA: Ares Capital (ARCC), VICI Properties (VICI), Altria (MO), and Pfizer (PFE). These stocks all offer dividend yi
-
Yahoo Finance analysis: Despite over 100% earnings payout ratio, Pfizer's (PFE) dividend likely sustainable
The analysis indicates that while Pfizer's stock is down over 50% from its 2021 high and its earnings payout ratio exceeds 100%, its cash dividend payout ratio is approximately 90%. As of Q2 2026, the
-
Pfizer (PFE) raises 2026 revenue guidance midpoint by $500 million, while Zoetis (ZTS) cuts its 2026 outlook
Pfizer (PFE) has raised the midpoint of its 2026 revenue guidance by $500 million, despite cutting its COVID-19 revenue expectation by $1 billion to about $4 billion. The company's underlying business
-
Analyst: Pfizer stock is a 'great buy-and-hold investment' despite 40% five-year decline, with 6.1% yield
An analyst from The Motley Fool suggests Pfizer (NYSE: PFE) stock is currently a strong buy-and-hold opportunity. While the company's shares have fallen nearly 40% over the past five years, they have
-
Wall Street analysts point out that high-dividend stocks of companies such as Pfizer and UPS are undervalued, with yields exceeding 6% and management's commitment to maintaining dividends.
Analysts believe that both Pfizer (PFE) and UPS (UPS) offer dividend yields exceeding 6% and their stock prices have fallen over 20% from five years ago, yet management has publicly committed to maint
-
The Motley Fool recommends Pfizer and Nintendo as top dividend stocks for August
The investment analysis firm highlights Pfizer (NYSE: PFE) and Nintendo (OTC: NTDOY) as two quality dividend stocks for investors to consider. Pfizer, a pharmaceutical giant, is currently discounted w
-
24/7 Wall St. analysts initiate Pfizer (PFE) with a Buy rating and a $32.36 price target, implying 15.27% upside over the next 12 months.
24/7 Wall St. analysts initiate Pfizer (PFE) with a Buy rating and a $32.36 price target, implying 15.27% upside over the next 12 months.
-
Pfizer ($PFE) Q2 adjusted EPS of $0.77 beats estimates of $0.68; revenue of $15.03B beats estimates of $14.41B, maintains FY revenue outlook.
Pfizer ($PFE) Q2 adjusted EPS of $0.77 beats estimates of $0.68; revenue of $15.03B beats estimates of $14.41B, maintains FY revenue outlook. The company reported a net loss of $248 million for the qu
-
Alnylam Pharmaceuticals' stock price has fallen by approximately 40% this year, but Wall Street analysts generally remain optimistic, with an average target price indicating about 50% upside potential.
Shares of biotechnology company Alnylam Pharmaceuticals (Nasdaq: ALNY) have fallen by approximately 40% year-to-date, but Wall Street analysts remain largely optimistic about its prospects. According
-
Yahoo Finance Analysis: Four High-Yield Dividend US Stocks Recommended, Including Pfizer and Altria
Yahoo Finance analysts recommend four high-yield dividend stocks suitable for a Roth IRA: Ares Capital (ARCC), VICI Properties (VICI), Altria (MO), and Pfizer (PFE). These stocks all offer dividend yi
-
Yahoo Finance analysis: Despite over 100% earnings payout ratio, Pfizer's (PFE) dividend likely sustainable
The analysis indicates that while Pfizer's stock is down over 50% from its 2021 high and its earnings payout ratio exceeds 100%, its cash dividend payout ratio is approximately 90%. As of Q2 2026, the
-
Pfizer (PFE) raises 2026 revenue guidance midpoint by $500 million, while Zoetis (ZTS) cuts its 2026 outlook
Pfizer (PFE) has raised the midpoint of its 2026 revenue guidance by $500 million, despite cutting its COVID-19 revenue expectation by $1 billion to about $4 billion. The company's underlying business
-
Analyst: Pfizer stock is a 'great buy-and-hold investment' despite 40% five-year decline, with 6.1% yield
An analyst from The Motley Fool suggests Pfizer (NYSE: PFE) stock is currently a strong buy-and-hold opportunity. While the company's shares have fallen nearly 40% over the past five years, they have
-
Wall Street analysts point out that high-dividend stocks of companies such as Pfizer and UPS are undervalued, with yields exceeding 6% and management's commitment to maintaining dividends.
Analysts believe that both Pfizer (PFE) and UPS (UPS) offer dividend yields exceeding 6% and their stock prices have fallen over 20% from five years ago, yet management has publicly committed to maint
-
The Motley Fool recommends Pfizer and Nintendo as top dividend stocks for August
The investment analysis firm highlights Pfizer (NYSE: PFE) and Nintendo (OTC: NTDOY) as two quality dividend stocks for investors to consider. Pfizer, a pharmaceutical giant, is currently discounted w
-
24/7 Wall St. analysts initiate Pfizer (PFE) with a Buy rating and a $32.36 price target, implying 15.27% upside over the next 12 months.
24/7 Wall St. analysts initiate Pfizer (PFE) with a Buy rating and a $32.36 price target, implying 15.27% upside over the next 12 months.
-
Pfizer ($PFE) Q2 adjusted EPS of $0.77 beats estimates of $0.68; revenue of $15.03B beats estimates of $14.41B, maintains FY revenue outlook.
Pfizer ($PFE) Q2 adjusted EPS of $0.77 beats estimates of $0.68; revenue of $15.03B beats estimates of $14.41B, maintains FY revenue outlook. The company reported a net loss of $248 million for the qu
- No data
Pfizer
24H Trending
-
1
Bitcoin, Gold, and Stocks: A Comparison of Risks, Returns, and Use Cases
-
2
Is it true that PI is buying Hongqi cars? Pi Network's latest developments and risk warnings
-
3
Cayman Islands Virtual Asset Trading Platforms: Regulatory Framework and Key Platforms Overview
-
4
What is MATE? An Analysis of the Asset, Project Positioning, and Current Status
-
5
FNB Protocol (FNB Coin) Value Analysis: Project Status and Investment Considerations
-
6
Deliq Finance (DLQ) Coin Analysis: Project Status and Market Liquidity
-
7
CORE and Satoshi Token Market Performance: 2023 Review and November 2026 Status
-
8
How is ZNX (ZENEX)? What are the future development prospects for ZNX?
-
9
Bloomberg survey shows China's factory activity expanded, but growth slowed for the first time since July.
-
10
OKX Futures Trading Tutorial and Beginner's Guide
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
